Buckingham Cuts Cephalon (CEPH) to Neutral Following Deal with Teva
Tweet Send to a Friend
An analyst at Buckingham Research downgraded shares of Cephalon (NASDAQ: CEPH) from Buy to Neutral in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


